Apexigen rises on positive data from cancer drug study
19/01/2023 16:42
** Shares of cancer drug developer Apexigen Inc APGN.O
rise 6.7% to $1.91
** Stock has risen in 8 of the past 10 sessions
** Co says its experimental drug showed expanded anti-tumor
immune responses in treatment of gastro-esophageal cancer in a
mid-stage study
** The drug candidate, sotigalimab, in combination with
radiation therapy led to increased activation of anti-cancer
immune cells, compared to radiation alone in rectal cancer
patients - APGN
** Sotigalimab is an antibody targeting CD40 protein which
produces inflammation in tumor cells and activates immune
response against it -APGN
** Including session moves, APGN down ~81% since it went
public through a SPAC deal in August
(Reporting by Mariam E Sunny)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq